SUMMARY
INTRODUCTION
Aripiprazole is a psychoactive compound acting as a dopamine D2 partial agonist, serotonin 5-HT(1A) partial agonist and serotonin 5-HT(2A) antagonist. Aripiprazole possesses a well-documented efficacy in the treatment of both positive and negative psychotic symptoms. Generally, it has been associated with modest neurological side effects and no significant adverse effects on serum prolactin levels, weight gain and metabolic alterations (Keck & McElroy 2003) , although the possible occurrence of neuroleptic malignant syndrome (Belvederi Murri et al. 2015) . However, the onset of hiccups has been rarely reported with the use of therapeutic drugs such as aripiprazole. Hiccup may be considered the product of the simultaneous involuntary spasmodic contraction of the diaphragm and glottic closure determining the suppression of the air entry into the trachea (Alderfer & Arciniegas 2006) . Although the exact etiology underlying the emergence of hiccup is poorly understood, the role of dopamine, serotonin and gamma amino butyric acid (GABA) has been well documented.
Here, we present the case of aripiprazole-induced hiccup in a young inpatient at his first psychiatric admission along with a review of the current literature about this specific topic.
CASE PRESENTATION
A 22-year-old male, originated from Albania, has been admitted to our psychiatric inpatient unit (IRCCS San Martino Hospital, Genoa) due to a brief manic episode with psychotic symptoms. The patient had no significant psychiatric episodes in the past. The first mood alterations occurred during the month before his admission, when he presented a brief manic episode, recovered spontaneously with no psychiatric treatment. When he was hospitalized, a bipolar I disorder, manic episode with psychotic features (according to DSM 5 diagnostic criteria) has been diagnosed. The patient signed a regular informed consent.
Specifically, he presented to the Emergency Unit of our hospital with the following psychotic (e.g., persecutory delusions, auditory hallucinations) and mood symptoms (e.g., reduced need for sleep, dysphoria and dissatisfaction, thought and speech acceleration, and psychomotor agitation). These symptoms occurred 3 days earlier, after a car accident during which he did not report any traumatic event. He underwent a brain computed tomography (CT) evaluation that showed no significant alterations before the admission to our psychiatric unit. Toxicological tests resulted negative and the patient did not present a positive history of abuse/dependence behavior as well. The patient's medical history was mute and no concurrent therapy had been prescribed.
The patient was tested at admission (T0) and before discharge (T1) with the following psychometric instruments: Clinical Global Impression (CGI) (Guy 1976) (T0 and T1 disease severity scale score=6 and 3, respectively; T0 and T1 global improving scale score=not evaluated and 1; T0 and T1 index of effectiveness scale=not assessed and 02, respectively) and Young Mania Rating Scale (YMRS) (Young et al., 1978 ) (T0 total score=36; T1 total score =2).
The patient has been treated with the following psychoactive treatments. At day 1, aripiprazole 14.6 mg and delorazepam 3 mg daily were administered by intramuscular formulation. After approximately 12 hours by the first aripiprazole injection, the patient started complaining about the onset of hiccup that was persistent even during the night. At day 2, psychoactive drugs were orally converted in 30 mg of aripiprazole and 1.5 mg of delorazepam daily, respectively. Lansoprazole 15 mg daily has been administered after 36 hours of continuous hiccup, with no relief. Thus, hypothesizing that the hiccup may be induced by aripiprazole, we suspended it after 48 hours, and asenapine was introduced at the initial daily dose of 20 mg. Interestingly, the hiccup spontaneously stopped 12 hours after the last aripiprazole ingestion. Using the Naranjo Adverse Drug Reaction Probability Scale (Naranjo et al. 1981 ), we found a probable relation between the titration of aripiprazole and the occurrence of persistent hiccup in our patient (Score 8). The psychotic and mood symptoms recovered completely at day 6 when the patient was discharged with asenapine 20 mg daily, delorazepam 0.5 mg, and lansoprazole 15 mg daily. The patient was then evaluated after 4 weeks from his discharge and the presence of hiccup has never been observed.
DISCUSSION
Hiccup is a spontaneous, myoclonic contraction of the diaphragm and intercostal muscles with closure of the glottis (Steger et al. 2015 ). Kolodzik and Eilers (1991) reported that, based on their duration, hiccups may be classified in: acute attacks (less than 48 hours), persistent hiccups (more than 48 hours), and intractable hiccups (more than 1 month according to Steger and colleagues (2015) or more than 2 months based on ). They are generated by a "reflex arc" (Chang & Lu 2012) which includes vagus and sympathetic nerves conveying somatic and visceral sensory signals, a central processing unit in the midbrain and motor fibers transmitting efferent stimulus by phrenic nerves to diaphragm and accessory nerves to the intercostal muscles, respectively . Dopamine, serotonin and gabaergic transmission (Ray et al. 2009 ) are presumably involved in the occurrence of hiccups, although the exact mechanisms underlying this adverse effect remain unclear. Any physical and chemicals irritants, inflammatory and neoplastic conditions evoking the hiccup reflex, are associated with the emergence of hiccup. Hiccup often occurs during gastroenteric and specific neurological diseases but it can be even related to multiple factors as well as specific medications (Steger et al. 2015) . Both first-and second-generation antipsychotics are often used to treat hiccup although this symptom may be also associated with the occurrence of similar adverse effects (Shapiro et al. 2003) . Specifically, olanzapine, haloperidol, and chlorpromazine demonstrated efficacy in treating hiccup, while aripiprazole, clozapine, perphenazine, and risperidone have been reported to be involved in its occurrence (Silverman et al. 2014 ).
To our knowledge there are, overall, 8 case reports and 1 retrospective study describing the link between aripiprazole administration and the onset of hiccup, and a total of 21 cases of aripiprazole-induced hiccup, with any apparent relation to the way of administration or the dosage, neither to patients' diagnosis.
CRITICAL REVIEW OF THE LITERATURE: MAIN IMPLICATIONS AND FUTURE PERSPECTIVES
First, Behere et al. (2007) described the case of a man presenting hiccup two days after the administration of aripiprazole 10 mg daily in add on to sodium valproate, oral antidiabetic drugs, and thyroxine supplement. Here, the emergence of this symptom seemed to be related to aripiprazole-induced hyponatremia. Indeed, after aripiprazole discontinuation and switching to quetiapine, sodium levels have been stabilized during the course of one week and hiccup spontaneously stopped. Another similar case about this topic (Ginsberg 2007 ) has been carefully summarized by Silverman et al. (2015) .
Other evidence suggested that hiccup may be related to the occurrence of hyponatremia (for more details, see George et al. (1996) ) although premarketing studies together with two other case reports (Behere et Thus, aripiprazole was increased to 25 mg daily and metoclopramide was initiated. Hiccup did not remit with metoclopramide neither with chlorpromazine treatment. Indeed, it stopped 24 hours after aripiprazole discontinuation and switching to risperidone. Although it is not possible to suppose a specific link between aripiprazoleinduced hiccup and the positive history of head injury, the frequent occurrence of this association is clinically interesting. However, our patient presented a car accident the day before his hospitalization, but he and his parents denied any traumatic events or signs of neurological impairment that were even excluded by the brain CT.
There In our report, the patient was drug naïve, and hiccup stopped after switching to asenapine, which possesses an antagonistic action on 5HT(1A) receptors as well as high affinity for D2 receptors (Correll 2010) , and this seems to be related with the hiccup improvement. Recently, De Filippis et al. (2015) presented four case reports of hiccup during aripiprazole and benzodiazepine combined treatment. In these cases, hiccup stopped after benzodiazepine discontinuation or add on with pregabalin. Indeed, hiccup arc reflex can be activated by GABA(a) receptors (benzodiazepine facilitating GABA(a) activation) in combination with voltagegated calcium ions, whereas it can be inhibited by GABA(b) receptors and calcium ion channel blockers such as pregabalin or gabapentin (alpha-2-delta ligands).
These findings seem to be confirmed by a retrospective study on 354 inpatients which were recruited during the course of 2013 at the Psychiatric Unit of Sant'Andrea Hospital, in Rome (Caloro et al. 2016 ). Here, 8 cases of hiccup were identified, with each case related to benzodiazepine treatment, 7 cases related to aripiprazole-benzodiazepine combination, and one case related to only benzodiazepine treatment. In three cases, hiccup resolution has been achieved through aripiprazole discontinuation and switching to other antipsychotics while in the remaining cases due to benzodiazepine discontinuation (in two of these cases through pregabalin addition and benzodiazepines discontinuation). Caloro et al. (2016) found an increased risk for developing hiccup in patients exposed to aripiprazole-benzodiazepine (in particular delorazepam) compared with those who were not exposed to this combination (OR= 68.69, 95% CI, 0.82 to 27.6). The risk was exclusive to the male sex, as no females presented a drug-related hiccup (OR=6.56, 95% CI from 1.61 to 26.73) and females were more exposed to the combination when compared to males indicating that the increased risk in male population was not related to a major exposure to the combination. Sexrelated factors are likely to be involved in the pathophysiology of hiccup (Caloro et al. 2016) as protracted hiccup appears predominant in males. To our knowledge, the only case of aripiprazole-related hiccup in a female patient was that presented by Hori and Nakamura (2014). The authors hypothesized a neurochemical interaction between dopaminergic and gabaergic transmissions, with a possible intermediation of the endocannabinoid system for this case. This may explain the increasing risk of hiccup in the patient treated with benzodiazepine-aripiprazole combination (Caloro et al. 2016 ).
The association with benzodiazepines has been observed even in our case, and was reported in other three reports as well (Silverman et (Silverman et al. 2014 ). In line with these observations, hiccup did not improve with lansoprazole in our patient although we did not introduce other psychoactive compounds such as metoclopramide Kani et al. 2015) . Surprisingly, in our case the hiccup stopped just after 12 hours from the last drug administration, perhaps due to the individual rapid metabolism or other individual factors but this may be only indirectly hypothesized.
There are other additional case-reports in which a reintroduction of aripiprazole after hiccup improvement Table 1 summarizes the most relevant studies about the association between aripiprazole use and hiccup.
CONCLUSIONS
In conclusion, hiccup is described, based on most of the reported evidence, not only as a common but a well described adverse effect related to aripiprazole treatment. However, other additional risk factors have been hypothesized to explain its occurrence. For instance, the association with hyponatremia (Ginsberg 2007 (Caloro et al. 2016) , and a particular link to other drugs have been reported. In particular, switching from a D2 high potency blocker to aripiprazole seems to increase the risk of hiccup occurrence, although other mechanisms, involving gabaergic and serotoninergic transmission, are presumably implicated (Yeh 2011 , Duvarci & Yilmaz 2013 . The importance of the interaction between aripiprazole and benzodiazepine in hiccup occurrence needs to be taken into consideration as well.
Clinicians should carefully monitor the relevance of concomitant treatments in case of aripiprazole-induced hiccup. In case of concurrent benzodiazepine consumption, a benzodiazepine suspension, where possible, should be considered and, alternatively, pregabalin may be considered for hiccup treatment. Otherwise, when aripiprazole suspension seems necessary, switching to another antipsychotic with D2 high potency profile may be provided.
More research is needed to better understand the mechanisms underlying aripiprazole-related hiccup, and exactly identify all the potential concurrent risk factors related to this complex phenomenon.
